HC Wainwright Issues Positive Estimate for BLFS Earnings

BioLife Solutions, Inc. (NASDAQ:BLFS - Free Report) - Investment analysts at HC Wainwright raised their Q1 2025 earnings per share estimates for shares of BioLife Solutions in a research report issued to clients and investors on Wednesday, March 5th. HC Wainwright analyst Y. Chen now anticipates that the medical equipment provider will post earnings per share of ($0.02) for the quarter, up from their previous forecast of ($0.10). HC Wainwright currently has a "Buy" rating and a $30.00 target price on the stock. The consensus estimate for BioLife Solutions' current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for BioLife Solutions' Q2 2025 earnings at ($0.06) EPS, Q3 2025 earnings at ($0.02) EPS, Q4 2025 earnings at ($0.06) EPS and FY2025 earnings at ($0.16) EPS.

Other equities research analysts also recently issued reports about the company. KeyCorp increased their price target on BioLife Solutions from $30.00 to $33.00 and gave the stock an "overweight" rating in a report on Friday, December 13th. Benchmark reissued a "buy" rating and issued a $30.00 price target on shares of BioLife Solutions in a research note on Thursday, December 19th. Craig Hallum upped their price objective on BioLife Solutions from $30.00 to $32.00 and gave the stock a "buy" rating in a research report on Wednesday, November 13th. TD Cowen increased their price objective on BioLife Solutions from $28.00 to $31.00 and gave the stock a "buy" rating in a report on Wednesday, November 13th. Finally, Northland Securities boosted their target price on BioLife Solutions from $28.00 to $31.00 and gave the company an "outperform" rating in a research note on Wednesday, January 8th. One analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. According to data from MarketBeat, BioLife Solutions currently has an average rating of "Moderate Buy" and a consensus price target of $29.86.

Remove Ads

BioLife Solutions Trading Down 4.7 %

Shares of BLFS stock traded down $1.24 on Monday, hitting $25.03. The stock had a trading volume of 174,925 shares, compared to its average volume of 349,149. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03. BioLife Solutions has a twelve month low of $14.84 and a twelve month high of $29.55. The company has a fifty day moving average price of $26.64 and a two-hundred day moving average price of $25.51. The firm has a market cap of $1.18 billion, a P/E ratio of -23.69 and a beta of 2.04.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last posted its earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.32. The company had revenue of $22.71 million during the quarter, compared to analyst estimates of $21.73 million. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. During the same period in the previous year, the company earned ($0.21) EPS.

Insider Activity at BioLife Solutions

In other BioLife Solutions news, CFO Troy Wichterman sold 987 shares of the company's stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $27.02, for a total value of $26,668.74. Following the sale, the chief financial officer now owns 121,779 shares in the company, valued at $3,290,468.58. This represents a 0.80 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Aby J. Mathew sold 7,604 shares of BioLife Solutions stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $27.33, for a total value of $207,817.32. Following the transaction, the executive vice president now owns 276,315 shares of the company's stock, valued at $7,551,688.95. This represents a 2.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 11,978 shares of company stock valued at $322,724. 2.20% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On BioLife Solutions

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of BioLife Solutions by 13.2% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 70,686 shares of the medical equipment provider's stock worth $1,835,000 after buying an additional 8,258 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of BioLife Solutions during the fourth quarter worth approximately $31,000. Point72 Asset Management L.P. bought a new stake in shares of BioLife Solutions during the fourth quarter worth approximately $11,113,000. ProShare Advisors LLC acquired a new position in shares of BioLife Solutions in the fourth quarter valued at approximately $282,000. Finally, Millennium Management LLC lifted its holdings in BioLife Solutions by 49.1% during the 4th quarter. Millennium Management LLC now owns 1,145,347 shares of the medical equipment provider's stock worth $29,733,000 after purchasing an additional 377,111 shares during the last quarter. 93.24% of the stock is owned by institutional investors.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.